CD274 and non-small cell lung carcinoma: A meta-analysis that studied 10 neoadjuvant immunotherapy studies and included a total of 461 NSCLC patients associated high levels of PD-L1 expression with an improved pathological response, noting 50% PD-L1 as a stronger predictive cutoff than 1% expression.